80405 研究原来是一项失败的临床试验,推定西妥昔单抗(CET)联合化疗的治疗效果优于贝伐珠单抗(BV)联合化疗。虽然从近 6000 个病例的研究分析得出,两组总的生存时间基本相似,但总生存时间从一般认为的 1.5 年左右可以延长至 3 年以上,这...
Subsequently, the combination of TAS-102 and bevacizumab (BV) has ... Y Yoshida,T Yamada,H Matsuoka,... - 《Annals of Oncology》 被引量: 0发表: 2019年 Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer BACKGROUND/AIM: The feasibility and oncological outcomes ...
Subsequently, the combination of TAS-102 and bevacizumab (BV) has been shown to extend median PFS to 3.7 months (C-TASK FORCE). However, this study included patients with 2nd line and 3rd line chemotherapy. Furthermore, combination chemotherapy of TAS-102 plus BV was reportedly associated with...
A Markov decision model simulating costs and quality-adjusted life-years (QALYs) related to TAS-102 plus bevacizumab combination therapy and TAS-102 monotherapy was constructed using R, version 3.4.3 with the heemod package (R Foundation for Statistical Computing, Vienna, Austria). The reference c...
TAS-102 in metastatic colorectal cancerdoi:10.1016/S1470-2045(17)30927-0Talha Khan BurkiElsevier BVLancet OncologyBurki TK. TAS-102 in metastatic colorectal cancer. Lancet Oncol. 2018;19(1):e18.
更多实用攻略教学,爆笑沙雕集锦,你所不知道的游戏知识,热门游戏视频7*24小时持续更新,尽在哔哩哔哩bilibili 视频播放量 2、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 窝趣窝趣窝趣66, 作者简介 ,相关视频:104,太空杀新模式,《国服寒冰射
Background TAS-102 improved overall survival of metastatic colorectal cancer (mCRC) patients with median progression-free survival (PFS) of 2.0 months (RECOURSE trial). Subsequently, the combination of TAS-102 and bevacizumab (BV) has been shown to extend median PFS to 3.7 months (C-TASK FORCE...
更多实用攻略教学,爆笑沙雕集锦,你所不知道的游戏知识,热门游戏视频7*24小时持续更新,尽在哔哩哔哩bilibili 视频播放量 0、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 窝趣窝趣窝趣66, 作者简介 ,相关视频:103,9 1,科吹解析D2 - T1的最强